HVTN 908

Status:Completed
Phase:Open Label
Principal Investigator(s):Erica Andersen-Nissen, PhD
Objective:HVTN 908 is a sub study of the HIV vaccine trial, HVTN 205. The purpose of this sub study is to better understand how a person's immune system responds to vaccines, particularly HIV vaccines. More specifically, researchers will determine whether early responses in the immune system help predict strong and long-lasting immunity.   Last updated May 25, 2022
Prevention Option(s):HIV Vaccine
Study Design:
Arms and Assigned Interventions
DescriptionA Participants receiving the JS7 DNA and MVA/HIV62 vaccinations in HVTN 205
Mode of Delivery
ARMsExperimental
Results: Elite control of HIV infection: implications for vaccine design
Official Code: NCT00908323
Related Publications:
Host genetic factors associated with susceptibility to HIV infection and progression of infection
Myd88 is required for an antibody response to retroviral infection
Trial Sponsors: NIAID (DAIDS ES 10806)
Start Date
End Date
July 1, 2009
July 1, 2012
Enrollment:47
Age range: 18 Years ↔ 50 Years
Population:Cisgender Men